Phase I/II trial of combination CCI-779 [TORISEL; temsirolimus; Wyeth] and bortezomib [VELCADE; Millenium Pharmaceuticals, Johnson and Johnson Pharmaceutical Research and Development LLC] in relapsed and/or relapsed/refractory multiple myeloma

Trial Profile

Phase I/II trial of combination CCI-779 [TORISEL; temsirolimus; Wyeth] and bortezomib [VELCADE; Millenium Pharmaceuticals, Johnson and Johnson Pharmaceutical Research and Development LLC] in relapsed and/or relapsed/refractory multiple myeloma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 May 2013

At a glance

  • Drugs Bortezomib (Primary) ; Temsirolimus (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Dec 2010 Results will be presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology
    • 09 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 12 May 2009 Planned number of patients changed from 31 to 68 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top